InsiderPulse
Dashboard

RVMD

Revolution Medicines, Inc.

Health CareRussell 2000

Revolution Medicines, Inc. insider trading

Revolution Medicines, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Redwood City, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent RVMD insider transactions

7 insiders traded RVMD on the open market between Sep 10, 2026 and Sep 18, 2026 — 24 sales worth $27.1M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$27.1M

24 of 24 on a 10b5-1 plan

Net
−$27.1M
Insiders
7

Open-market purchases (code P) and sales (code S) from Revolution Medicines, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every RVMD Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

RVMD insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 11 insiders traded RVMD on the open market: 2 purchases worth $60M and 143 sales worth $106M, 142 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 86 sales ($84.8M), by 8 insiders.

QuarterBoughtSold
Q2 2026—−$41.9M25 sales · 24 on a plan
Q1 2026—−$19M31 sales · all on a plan
Q4 2025—−$16.6M17 sales · all on a plan
Q3 2025—−$7.4M13 sales · all on a plan
Q2 2025—−$1.7M8 sales · all on a plan
Q1 2025—−$1M7 sales · all on a plan
Q4 2024+$60M2 buys−$13.1M23 sales · all on a plan
Q3 2024—−$5.3M19 sales · all on a plan
Largest purchase
+$35M of RVMD by Schroeder Thilo (Director) on Dec 05, 2024.
Largest sale
−$18M of RVMD by Goldsmith Mark A (President and Chief Executive Officer · Director) on Apr 15, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Anders Jack10b5-1

    Chief Financial Officer

    −$1.6M

    Jun 24, 2026

    9,496 sh · $168.20

  • Anders Jack10b5-1

    Chief Financial Officer

    −$956.4K

    Jun 24, 2026

    5,651 sh · $169.24

  • Anders Jack10b5-1

    Chief Financial Officer

    −$761.9K

    Jun 24, 2026

    4,553 sh · $167.35

  • Anders Jack10b5-1

    Chief Financial Officer

    −$51.1K

    Jun 24, 2026

    300 sh · $170.32

  • Horn Margaret A10b5-1

    Chief Operating Officer

    −$4.7M

    Jun 17, 2026

    29,600 sh · $160.12

  • Goldsmith Mark A10b5-1

    President and Chief Executive Officer · Director

    −$1.6M

    Jun 16, 2026

    10,020 sh · $156.12

  • Mancini Anthony

    Chief Global Commercialization Officer

    −$720.5K

    Jun 16, 2026

    4,615 sh · $156.12

  • Kelsey Stephen Michael10b5-1

    President, Research and Development

    −$651.8K

    Jun 16, 2026

    4,175 sh · $156.12

  • Anders Jack10b5-1

    Chief Financial Officer

    −$425K

    Jun 16, 2026

    2,722 sh · $156.12

  • Cislini Jeff10b5-1

    General Counsel

    −$336.8K

    Jun 16, 2026

    2,157 sh · $156.12

  • Horn Margaret A10b5-1

    Chief Operating Officer

    −$9.7M

    Jun 15, 2026

    60,400 sh · $160.17

  • Horn Margaret A10b5-1

    Chief Operating Officer

    −$688.3K

    Jun 11, 2026

    4,600 sh · $149.64

  • Horn Margaret A10b5-1

    Chief Operating Officer

    −$267.7K

    Jun 11, 2026

    1,800 sh · $148.72

  • Horn Margaret A10b5-1

    Chief Operating Officer

    −$189.7K

    Jun 11, 2026

    1,315 sh · $144.28

  • Horn Margaret A10b5-1

    Chief Operating Officer

    −$128.5K

    Jun 11, 2026

    885 sh · $145.15

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Revolution Medicines, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Redwood City, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001628171

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought RVMD

What the stock actually did in the 90 days following each open-market purchase

Don't check RVMD — let it ping you

Get told the moment an insider moves on RVMD

Pro watches Revolution Medicines, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add RVMD to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track RVMD on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read RVMD insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

RYTMSMMTSNDXSRRKTGTXVERAVKTXXENEZLABATTODNTHUTHR
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are RVMD insiders buying or selling?
Between Sep 10, 2026 and Sep 18, 2026, 7 Revolution Medicines, Inc. insiders made no open-market purchases and 24 sales worth $27.1M, a net sale of $27.1M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much RVMD stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 11 Revolution Medicines, Inc. insiders made 2 open-market purchases worth $60M and 143 sales worth $106M. 142 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 86 sales ($84.8M). The largest purchase was Schroeder Thilo buying $35M on Dec 05, 2024. The largest sale was Goldsmith Mark A selling $18M on Apr 15, 2026.
What was the largest recent RVMD insider trade?
Kelsey Stephen Michael (See Remarks) sold $4.3M of RVMD stock on Sep 11, 2026 at about $201.75 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy RVMD shares?
No open-market purchase by a Revolution Medicines, Inc. insider appears in the filings from Sep 10, 2026 to Sep 18, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Schroeder Thilo buying $35M on Dec 05, 2024.
Where does RVMD insider trading data come from?
From the Form 4 filings Revolution Medicines, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.